Susan Dexter
Chief Tech/Sci/R&D Officer chez SONNET BIOTHERAPEUTICS HOLDINGS, INC.
Fortune : 2 846 $ au 31/03/2024
Profil
Ms. Susan Dexter is a Chief Technical Officer at Sonnet BioTherapeutics, Inc., a Chief Technical Officer at Sonnet BioTherapeutics Holdings, Inc. and an Independent Non-Executive Director at Sartorius Stedim Biotech SA. She is on the Board of Directors at Sartorius Stedim Biotech SA, Virica Biotech, Inc. and Virocell, Inc. Ms. Dexter was previously employed as a Managing Director by Latham BioPharm Group, Inc., a Chief Business Officer by Xcellerex, Inc., a Vice President-Business Development by The Dow Chemical Co.(Delaware), an Associate Director-Business Development by Lonza Biologics Plc, a Vice President-Business & Strategic Development by Collaborative BioAlliance Inc & Collaborative Smithfield Corp, a Director & Chief Marketing Officer by FUJIFILM Diosynth Biotechnologies Texas LLC, and a Professor-Emeritus by University College London.
She also served on the board at BioSense Technologies and City of College Station (Texas).
She received her undergraduate degree from Harvard University and an undergraduate degree from American University.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
14/06/2023 | 1 530 ( 0,05% ) | 2 846 $ | 31/03/2024 |
Postes actifs de Susan Dexter
Sociétés | Poste | Début |
---|---|---|
SARTORIUS STEDIM BIOTECH | Director/Board Member | 07/04/2015 |
SONNET BIOTHERAPEUTICS HOLDINGS, INC. | Chief Tech/Sci/R&D Officer | 01/04/2020 |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | Chief Tech/Sci/R&D Officer | 01/05/2020 |
Virocell, Inc. | Director/Board Member | - |
Virica Biotech, Inc.
Virica Biotech, Inc. Pharmaceuticals: MajorHealth Technology Virica Biotech, Inc. is a Canadian company that specializes in viral medicines, including gene therapies, vaccines, and oncolytic viruses. The company is based in Ottawa, Canada and was founded in 2018 by Ella Korets-Smith and Jean-Simon Diallo. The company has developed a new product category of viral sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. The company's purpose is to realize the promise of viral medicines and extend the horizons of human healthcare. Jean-Simon Diallo has been the CEO since 2018. | Director/Board Member | - |
Anciens postes connus de Susan Dexter
Sociétés | Poste | Fin |
---|---|---|
Latham BioPharm Group, Inc.
Latham BioPharm Group, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sia Partners SASU, Latham BioPharm Group, Inc. is a leading life science consulting private company that works with pharmaceutical, biotech, CROs, academia, and medical device/diagnostic companies to solve complex business, regulatory, and product development challenges. The company was founded in 1996 by Peter Latham and is based in Elkridge, MD. LBG's core services include comprehensive functional expertise in vaccines, therapeutics, cell & gene therapy, medical devices, and diagnostics. The company provides technical expertise, quality oversight, strategic analysis, and knowledge management necessary to successfully navigate the complex roadmap of life sciences product development. LBG has helped clients identify, evaluate, fund, manage, and monetize opportunities, generating over $1 billion in non-dilutive funding and over $100 million in licensing fees and investments. Latham BioPharm Group was acquired by Sia Partners SASU on October 14, 2022. | Corporate Officer/Principal | 01/01/2020 |
Xcellerex, Inc.
Xcellerex, Inc. Pharmaceuticals: MajorHealth Technology Xcellerex, Inc. manufactures and provides equipment to produce bio-molecules. Its products and services include FlexFactory, a bioprocess manufacturing platform that handles the production of bio-products, such as vaccines, yeast and insulins. The company was founded by Parrish M. Galliher in 2002 and was headquartered in Marlborough, MA. | Corporate Officer/Principal | 01/09/2008 |
DOW CHEMICAL COMPANY (THE) | Corporate Officer/Principal | 01/04/2004 |
Collaborative BioAlliance Inc & Collaborative Smithfield Corp
Collaborative BioAlliance Inc & Collaborative Smithfield Corp Pharmaceuticals: MajorHealth Technology Part of Dow, Inc., Collaborative BioAlliance Inc & Collaborative Smithfield Corp is an American company that develops and manufactures biopharmaceutical drugs. The private company is based in NY. Collaborative BioAlliance Inc & Collaborative Smithfield was acquired by The Dow Chemical Co., a SUB of Dow, Inc. from Engelhard Long Island, Inc. on November 17, 2000. | Corporate Officer/Principal | 01/04/2003 |
░░░░░ ░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Susan Dexter
Harvard University | Undergraduate Degree |
American University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
SARTORIUS STEDIM BIOTECH | Health Technology |
SONNET BIOTHERAPEUTICS HOLDINGS, INC. | Health Technology |
Entreprise privées | 11 |
---|---|
The Dow Chemical Co.
The Dow Chemical Co. Chemicals: SpecialtyProcess Industries The Dow Chemical Co. engages in the manufacture and distribution of chemicals, plastics, industrial and agricultural products. It serves agriculture, automotive, building and construction, consumer, electronic materials, infrastructure, packaging, product finder and product safety industries. The company was founded by Herbert Henry Dow in 1897 and is headquartered in Midland, MI. | Process Industries |
Xcellerex, Inc.
Xcellerex, Inc. Pharmaceuticals: MajorHealth Technology Xcellerex, Inc. manufactures and provides equipment to produce bio-molecules. Its products and services include FlexFactory, a bioprocess manufacturing platform that handles the production of bio-products, such as vaccines, yeast and insulins. The company was founded by Parrish M. Galliher in 2002 and was headquartered in Marlborough, MA. | Health Technology |
Lonza Biologics Plc
Lonza Biologics Plc Miscellaneous Commercial ServicesCommercial Services Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom. | Commercial Services |
Collaborative BioAlliance Inc & Collaborative Smithfield Corp
Collaborative BioAlliance Inc & Collaborative Smithfield Corp Pharmaceuticals: MajorHealth Technology Part of Dow, Inc., Collaborative BioAlliance Inc & Collaborative Smithfield Corp is an American company that develops and manufactures biopharmaceutical drugs. The private company is based in NY. Collaborative BioAlliance Inc & Collaborative Smithfield was acquired by The Dow Chemical Co., a SUB of Dow, Inc. from Engelhard Long Island, Inc. on November 17, 2000. | Health Technology |
City of College Station (Texas) | Government |
Virocell, Inc. | |
FUJIFILM Diosynth Biotechnologies Texas LLC
FUJIFILM Diosynth Biotechnologies Texas LLC Pharmaceuticals: OtherHealth Technology Fujifilm Diosynth Biotechnology Texas LLC manufactures and distributes biopharmaceutical vaccines. The company was founded on February 25, 2011 and is headquartered in College Station, TX. | Health Technology |
Sonnet BioTherapeutics, Inc.
Sonnet BioTherapeutics, Inc. BiotechnologyHealth Technology SONNET BioTherapeutics, Inc. is a clinical stage biotechnology company, which engages in the development of biologic drugs with single- or bi-specific mechanisms of action. Its pipeline include FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues. The company was founded by Pankaj Mohan and John K. Cini in 2015 and is headquartered in Princeton, NJ. | Health Technology |
BioSense Technologies | |
Latham BioPharm Group, Inc.
Latham BioPharm Group, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Sia Partners SASU, Latham BioPharm Group, Inc. is a leading life science consulting private company that works with pharmaceutical, biotech, CROs, academia, and medical device/diagnostic companies to solve complex business, regulatory, and product development challenges. The company was founded in 1996 by Peter Latham and is based in Elkridge, MD. LBG's core services include comprehensive functional expertise in vaccines, therapeutics, cell & gene therapy, medical devices, and diagnostics. The company provides technical expertise, quality oversight, strategic analysis, and knowledge management necessary to successfully navigate the complex roadmap of life sciences product development. LBG has helped clients identify, evaluate, fund, manage, and monetize opportunities, generating over $1 billion in non-dilutive funding and over $100 million in licensing fees and investments. Latham BioPharm Group was acquired by Sia Partners SASU on October 14, 2022. | Commercial Services |
Virica Biotech, Inc.
Virica Biotech, Inc. Pharmaceuticals: MajorHealth Technology Virica Biotech, Inc. is a Canadian company that specializes in viral medicines, including gene therapies, vaccines, and oncolytic viruses. The company is based in Ottawa, Canada and was founded in 2018 by Ella Korets-Smith and Jean-Simon Diallo. The company has developed a new product category of viral sensitizers (VSE™) that removes the barriers to manufacturing effective viral medicines at scale. The company's purpose is to realize the promise of viral medicines and extend the horizons of human healthcare. Jean-Simon Diallo has been the CEO since 2018. | Health Technology |